Positron Emission Tomography and Computed Tomography Scan

PROCEDURE7 trials

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University, National Cancer Institute (NCI), Mayo Clinic, City of Hope Medical Center

Conditions

Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaDiffuse Midline Glioma, H3 K27M-MutantHepatocellular CarcinomaMantle Cell LymphomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma

Early Phase 1

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

WithdrawnNCT05111314

Mayo ClinicHepatocellular Carcinoma

Start: 2022-02-11End: 2023-08-14Updated: 2023-11-07

Phase 1

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Active, not recruitingNCT05627245

National Cancer Institute (NCI)Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma +11

Start: 2023-03-01End: 2026-09-01Target: 48Updated: 2026-04-03

Phase 2

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

CompletedNCT03513952

National Cancer Institute (NCI)Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma +21

Start: 2019-06-05End: 2024-04-01Updated: 2024-07-26

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

RecruitingNCT05077735

Mayo ClinicDiffuse Midline Glioma, H3 K27M-Mutant

Start: 2021-10-11End: 2027-10-15Target: 29Updated: 2026-01-20

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

RecruitingNCT06572618

City of Hope Medical CenterMantle Cell Lymphoma

Start: 2025-01-22End: 2027-01-08Target: 27Updated: 2026-03-13

Unknown Phase

Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

CompletedNCT02989623

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityProstate Cancer

Start: 2015-09-01End: 2019-04-25Updated: 2025-04-24

Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer

TerminatedNCT03053960

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityOral Cavity Squamous Cell Carcinoma

Start: 2015-11-24End: 2018-11-01Updated: 2025-04-30

Related Papers

Dual HDAC and EZH2 inhibition modulates RFX5 activity to increase the immunogenicity of germinal center-derived B-cell lymphoma

Blood2025-11-03

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Blood2024-11-052 citations

Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma

Blood2024-11-051 citations

A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma.

Journal of Clinical Oncology2024-01-29

ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA

Hematological Oncology2023-06-01

A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).

Journal of Clinical Oncology2019-05-202 citations